Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33620
Abstract: Cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, are approved to treat hormone receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative advanced breast cancer (ABC) and are associated with hematologic toxicity. African American women, who are… read more here.
Keywords: ethnic neutropenia; advanced breast; breast cancer; cancer ... See more keywords
Benign ethnic neutropenia.
Sign Up to like & getrecommendations! Published in 2019 at "Blood reviews"
DOI: 10.1016/j.blre.2019.06.003
Abstract: Benign ethnic neutropenia (BEN) is one of the most common causes of chronic neutropenia seen in individuals of African, Middle Eastern and West Indian descent, affecting many individuals worldwide. Despite its prevalence, many physicians are… read more here.
Keywords: ethnic neutropenia; ben; condition; benign ethnic ... See more keywords